CytomX Therapeutics CFO Carlos Campoy to depart Sept 30; Chris Ogden named principal financial officer

CytomX Therapeutics, Inc.

Carlos Campoy, SVP and CFO, expected to terminate employment effective Sept 30, 2022.
Chris Ogden, SVP Finance and Accounting, assumes principal financial and principal accounting officer roles effective immediately.
Ogden's biographical details incorporated by reference from April 2022 proxy statement.
No family relationships or related party transactions between Ogden and the Company.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Carlos Campoy

SVP, Chief Financial Officer

CTMX · CytomX Therapeutics, Inc.

Effective: 2022-09-30
Successor: Chris Ogden
Filed: September 23, 2022, 7:59 PM ET

the planned departure of Carlos Campoy, the Company's SVP, Chief Financial Officer and former principal financial officer and principal accounting officer, whose employment is expected to terminate effective as of September 30, 2022.

Appointed

Chris Ogden

Principal Financial Officer and Principal Accounting Officer

CTMX · CytomX Therapeutics, Inc.

Effective: 2022-09-21
Filed: September 23, 2022, 7:59 PM ET

designated Chris Ogden, the Company's Senior Vice President, Finance and Accounting, to assume the responsibilities of principal financial officer and principal accounting officer, effective immediately

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Carlos Campoy departed as SVP, Chief Financial Officer at CytomX Therapeutics, Inc..

Action: planned departure
Role: SVP, Chief Financial Officer

Exact text from the filing

the planned departure of Carlos Campoy, the Company's SVP, Chief Financial Officer and former principal financial officer and principal accounting officer, whose employment is expected to terminate effective as of September 30, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Chris Ogden was appointed as Principal Financial Officer and Principal Accounting Officer at CytomX Therapeutics, Inc..

Action: designated
Role: Principal Financial Officer and Principal Accounting Officer

Exact text from the filing

designated Chris Ogden, the Company's Senior Vice President, Finance and Accounting, to assume the responsibilities of principal financial officer and principal accounting officer, effective immediately

View on SEC.gov

CytomX Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-250137

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.